Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).Phase 3NCT00645086

Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis

A Phase 3 study testing clarithromycin extended-release tablets and clarithromycin immediate-release tablets in people with Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)., run by Abbott at 146 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

To compare the efficacy of a 5-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID) in the treatment of acute bacterial exacerbation of chronic bronchitis. Read more about this study

Who is it for?: Ages 40 years and older
Conditions the study is for: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).
What is being tested?: clarithromycin extended-release tablets and clarithromycin immediate-release tablets
Type of treatment: Pill or oral medicine
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 465 participants
Where: 146 sitesin 3 countries
Study dates: Dec 2002to Apr 2004
Phase: Phase 3
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 40 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Ambulatory subject who does not require intravenous antibiotic therapy.
Subject who has a medical history of chronic bronchitis.
A history of regular medication use (>=3 consecutive months within the past 2 years) to treat pulmonary disease.
Subject must have evidence of pulmonary function test abnormalities.
The onset of signs and symptoms of the current exacerbation must occur within 14 days before Evaluation 1.

Who cannot join

Medical history of hypersensitivity, allergic or adverse reactions to clarithromycin, erythromycin, or any of the macrolide antibiotics.
A female who is pregnant or is lactating.
Subject who has suspected or known (positive chest radiograph) pneumonia.
Subject who has evidence of significant bronchiectasis (by CT) or atelectasis, active tuberculosis or other mycobacterial infection, bullous emphysema, pulmonary embolism, lung abscess, tumor (primary or metastatic) involving the lung, pleural effusion, or cystic fibrosis that could confound the assessment of signs and symptoms of ABECB.
Subject who requires parenteral antibiotic therapy.
Subject who requires hospitalization for treatment of current episode of ABECB.

Show all 10Show fewer

Subject who has any other infection or condition, which necessitates use of a concomitant systemic antibiotic.
Subject who has any underlying condition/disease, which would be likely to interfere with the completion of the course or absorption of study drug therapy or follow-up.
Subject who has a severe or complicated lower respiratory tract infection or a severely compromised respiratory status (i.e., oxygen dependent, requiring hospitalization).
Known significant renal or hepatic impairment.

Trial locations and contacts

146 sites in 3 countries.

Country

City, postcode or hospital

146 sites in 3 countries

United States135 sites

Study site
Astoria, New York, 11102
Study site
Atlanta, Georgia, 30342
Study site
Auburn, Maine, 04210
Study site
Austin, Texas, 78728
Study site
Bamberg, South Carolina, 29003
Study site
Baton Rouge, Louisiana, 70816
Study site
Beaumont, Texas, 77701
Study site
Bensalem, Pennsylvania, 19020
Study site
Birmingham, Alabama, 35235
Study site
Birmingham, Alabama, 35242
Study site
Blackwood, New Jersey, 08012
Study site
Blue Ridge, Georgia, 30513
Study site
Brandon, Florida, 33511
Study site
Bronxville, New York, 10708
Study site
Buffalo, New York, 14215
Study site
Camden, Arkansas, 71701
Study site
Camillus, New York, 13031
Study site
Chardon, Ohio, 44024
Study site
Chattanooga, Tennessee, 37404
Study site
Chester, Maryland, 21619
Study site
Chesterfield, Missouri, 63017
Study site
Chicago, Illinois, 60612
Study site
Christianburg, Virginia, 24073
Study site
Clarksville, Tennessee, 37043
Study site
Clovis, California, 93611
Study site
Coeur d'Alene, Idaho, 83814
Study site
Colleyville, Texas, 76034
Study site
Colorado Springs, Colorado, 80909
Study site
Columbiana, Alabama, 35051
Study site
Corona, California, 92879
Study site
Cranston, Rhode Island, 02920
Study site
DeLand, Florida, 32720
Study site
DeWitt, Michigan, 48820
Study site
Ducktown, Tennessee, 37326
Study site
East Providence, Rhode Island, 02914
Study site
El Paso, Texas, 79925
Study site
Elkhart, Indiana, 46514
Study site
Eugene, Oregon, 97404
Study site
Evansville, Indiana, 47712
Study site
Fleetwood, Pennsylvania, 19522
Study site
Fort Gordon, Georgia, 30905
Study site
Fort Lauderdale, Florida, 33316
Study site
Fort Worth, Texas, 76135
Study site
Fountain View, California, 92708
Study site
Fresno, California, 93703
Study site
Gainesville, Florida, 32605
Study site
Glendale, Arizona, 85306
Study site
Greensboro, North Carolina, 27401
Study site
Greer, South Carolina, 29651
Study site
Hines, Illinois, 60141
Study site
Hoover, Alabama, 35216
Study site
Huntington Beach, California, 92647
Study site
Indianapolis, Indiana, 46254
Study site
Jefferson City, Missouri, 65109
Study site
Johnson City, Tennessee, 37601
Study site
Lake Oswego, Oregon, 97035
Study site
Lakewood, California, 90712
Study site
Largo, Florida, 33770
Study site
Lexington, Kentucky, 40508
Study site
Livonia, Michigan, 48152
Study site
Loveland, Colorado, 80538
Study site
Marietta, Georgia, 30060
Study site
Mechanicsville, Virginia, 23111
Study site
Medford, Oregon, 97504
Study site
Merritt Island, Florida, 32953
Study site
Metairie, Louisiana, 70006
Study site
Miami, Florida, 33157
Study site
Miami, Florida, 33186
Study site
Milwaukee, Wisconsin, 53125
Study site
Missoula, Montana, 59804
Study site
Mobile, Alabama, 36608
Study site
Mogadore, Ohio, 44260
Study site
Montgomery, Alabama, 36106
Study site
Mount Laurel, New Jersey, 08054
Study site
Murray, Kentucky, 42071
Study site
New Berlin, Wisconsin, 53151
Study site
New Orleans, Louisiana, 70128
Study site
New Port Richey, Florida, 34652
Study site
New Tazewell, Tennessee, 37825
Study site
New York, New York, 10016
Study site
Newport News, Virginia, 23606
Study site
Oklahoma City, Oklahoma, 73112
Study site
Omaha, Nebraska, 68134
Study site
Orland Park, Illinois, 60462
Study site
Orlando, Florida, 32806
Study site
Ozark, Alabama, 36360
Study site
Panama City, Florida, 32405
Study site
Pasadena, California, 91105
Study site
Philadelphia, Pennsylvania, 19138
Study site
Philadelphia, Pennsylvania, 19142
Study site
Philadelphia, Pennsylvania, 19148
Study site
Phoenix, Arizona, 85006
Study site
Portland, Oregon, 97219
Study site
Rancho Cucamonga, California, 91730
Study site
Richmond, Virginia, 23226
Study site
Ridley Park, Pennsylvania, 19078
Study site
Rome, Georgia, 30165-1698
Study site
Roseville, California, 95661
Study site
Saginaw, Michigan, 48602
Study site
Saint Joseph, Michigan, 49085
Study site
Salt Lake City, Utah, 84102
Study site
San Angelo, Texas, 76904
Study site
San Antonio, Texas, 78233
Study site
San Diego, California, 92103
Study site
San Diego, California, 92117
Study site
San Diego, California, 92123
Study site
San Jose, California, 95128
Study site
Savannah, Tennessee, 38372
Study site
Selmer, Tennessee, 38375
Study site
Simpsonville, South Carolina, 29681
Study site
Spartanburg, South Carolina, 29302
Study site
Spokane, Washington, 99204
Study site
Spokane, Washington, 99207
Study site
Spokane, Washington, 99216
Study site
Springfield, Missouri, 65802
Study site
St Louis, Missouri, 63110-1093
Study site
Sun City West, Arizona, 85375
Study site
Sunset, Louisiana, 70584
Study site
Sylmar, California, 91342
Study site
Tallahassee, Florida, 36078
Study site
Tampa, Florida, 33614
Study site
Temecula, California, 92591
Study site
Toledo, Ohio, 43614
Study site
Toledo, Ohio, 43617
Study site
Toms River, New Jersey, 08755
Study site
Torrance, California, 90505
Study site
Tucson, Arizona, 85712
Study site
Tucson, Arizona, 85746
Study site
Upland, California, 91786
Study site
Waterbury, Connecticut, 06708
Study site
West Caldwell, New Jersey, 07007
Study site
Wheat Ridge, Colorado, 80033
Study site
Wichita, Kansas, 67207
Study site
Winston-Salem, North Carolina, 27103
Study site
Zanesville, Ohio, 43701

Other trials in United States

Canada10 sites

Study site
Coquitlam, British Columbia, V3K 3P4
Study site
Kitchener, Ontario, N2C 2N9
Study site
Markham, Ontario, L6B 1A1
Study site
Mississauga, Ontario, L5M 2V8
Study site
Saskatoon, Saskatchewan, S7H 5M3
Study site
Scarborough Village, Ontario, M1B 4Z8
Study site
Sherbrooke, Quebec, J1J 2B8
Study site
Ste-Foy, Quebec, G1V 4G5
Study site
Toronto, Ontario, M9W 4L6
Study site
Winnipeg, Manitoba, R3R 0C5

Other trials in Canada

Puerto Rico1 site

Study site
San Juan, 00921-3201

Other trials in Puerto Rico

About this study

Official title: A Phase III Comparative Efficacy Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Subjects With Acute Bacterial Exacerbation of Chronic Bronchitis.

Conditions: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).
Being tested: clarithromycin extended-release tablets, clarithromycin immediate-release tablets

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

clarithromycin extended-release tabletsDrug
Also called ABT-268, Biaxin, clarithromycin
5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
clarithromycin immediate-release tabletsDrug
Also called ABT-268, Biaxin, clarithromycin
7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)

Study groups in NCT00645086
Study group	Role	What they receive
A	Active comparator	Not described Receives: Drug: clarithromycin extended-release tablets
B	Active comparator	Not described Receives: Drug: clarithromycin immediate-release tablets

What is being measured

The primary outcome is the main question the study is designed to answer.

Clinical Response
Measured: 23 days
Bacteriologic Response
Measured: 23 days

Secondary outcomes (3)

Adverse events assessment
Measured: 42 days with follow-up to a satisfactory conclusion
Physical exam; Vital signs; Use of other medications and supplements
Measured: 42 days
Laboratory evaluations
Measured: 23 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Dec 2002Apr 2004

First posted27 Mar 2008 (estimated)
Study startDec 2002
Primary completionApr 2004

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).Studies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Investigator
Enrolment: 465 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT00645086
Sponsor's protocol ID: M02-472
Status last verified: Mar 2008
First submitted: 24 Mar 2008
Last updated: 27 Mar 2008
Results posted: No

Study at a glance

From the registry record, last updated by the sponsor on 27 Mar 2008. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: A Phase III Comparative Efficacy Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Subjects With Acute Bacterial Exacerbation of Chronic Bronchitis.
ClinicalTrials.gov ID: NCT00645086
Acronym / sponsor ID: M02-472
Conditions: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).
Phase: Phase 3
Study type: Interventional
Recruitment status: Completed
Enrolment: 465 participants (actual)
Lead sponsor: AbbottIndustry (pharma, biotech, devices)
Study start: Dec 2002
Primary completion: Apr 2004 (actual)
First posted: 27 Mar 2008 (estimated)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind (participant, investigator)
Number of arms: 2

Arm	Type	Receives
A	Active comparator	Drug: clarithromycin extended-release tablets
B	Active comparator	Drug: clarithromycin immediate-release tablets

Who may qualify

Ages: 40 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (5 listed)

Ambulatory subject who does not require intravenous antibiotic therapy.
Subject who has a medical history of chronic bronchitis.
A history of regular medication use (>=3 consecutive months within the past 2 years) to treat pulmonary disease.
Subject must have evidence of pulmonary function test abnormalities.
The onset of signs and symptoms of the current exacerbation must occur within 14 days before Evaluation 1.

Key exclusion criteria (10 listed)

Medical history of hypersensitivity, allergic or adverse reactions to clarithromycin, erythromycin, or any of the macrolide antibiotics.
A female who is pregnant or is lactating.
Subject who has suspected or known (positive chest radiograph) pneumonia.
Subject who has evidence of significant bronchiectasis (by CT) or atelectasis, active tuberculosis or other mycobacterial infection, bullous emphysema, pulmonary embolism, lung abscess, tumor (primary or metastatic) involving the lung, pleural effusion, or cystic fibrosis that could confound the assessment of signs and symptoms of ABECB.
Subject who requires parenteral antibiotic therapy.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
clarithromycin extended-release tabletsAlso: ABT-268, Biaxin, clarithromycin5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)	Drug	A
clarithromycin immediate-release tabletsAlso: ABT-268, Biaxin, clarithromycin7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)	Drug	B

Primary outcome

Clinical Response
Time frame: 23 days
Bacteriologic Response
Time frame: 23 days

3 secondary outcomes

Adverse events assessment
Time frame: 42 days with follow-up to a satisfactory conclusion
Physical exam; Vital signs; Use of other medications and supplements
Time frame: 42 days
Laboratory evaluations
Time frame: 23 days

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2008.

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

The record lists no contact. Use the official record to reach the sponsor.

146 sites in 3 countries: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Mar 2008. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 146 sites in United States, Canada, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Response (time frame: 23 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00645086.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2008; AzTrials last refreshed its copy on 7 Nov 2026.